TORONTO, Dec. 15, 2025 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: PF0) a premier artificial intelligence (AI) company that is transforming clinical trials with AI powered precision analytics in the pharmaceutical industry, today announced the completion of its Critical Path Innovation Meeting (CPIM) with the U.S. Food and Drug Administration (FDA). During this scientific exchange, FDA provided feedback on NetraAI—NetraMark's explainable ...

Company Performance - Simulations Plus, Inc. reported third-quarter fiscal 2025 adjusted earnings of 45 cents per share, a 66.7% increase year over year, surpassing the Zacks Consensus Estimate of 26 cents per share [1] - Quarterly revenues increased by 10% year over year to $20.4 million, driven by growth in software and services, along with a $2.4 million contribution from the Pro-ficiency acquisition [2] - Organic revenue fell by 4%, primarily due to reduced QSP/QST software sales and a decline in biosimulation services revenue [3] Strategic Developments - The company underwent a strategic reorganization, transitioning to a functionally-driven operating model to streamline operations and focus on high-growth areas [4] - Simulations Plus announced a $1 million investment in Nurocor, a cloud-based software company, as part of its Corporate Development Initiative targeting early-stage technology companies [5] Market Outlook - The clinical trial technology and services sector was estimated at $25.7 billion in 2024, with a projected CAGR of 15.5% from 2025 to 2030, driven by the adoption of digital health technologies [6] - Despite macroeconomic challenges, the company is committed to innovation, focusing on integrating AI-driven capabilities across its product lines [7] Financial Details - The gross margin for the quarter was 64%, down from 71.5% in the prior-year quarter, attributed to a $2 million rise in cost of revenues [16] - Total operating expenses increased by 667% to $87.3 million due to a one-time non-cash impairment charge of $77.2 million [17] - Cash and short-term investments as of May 31, 2025, were $28.5 million, up from $21.5 million as of February 28, 2024 [18] Guidance Revision - The company revised its fiscal 2025 revenue guidance to between $76 million and $80 million, down from the previous estimate of $90-$93 million [21] - Adjusted earnings per share are now expected to be in the range of 93 cents to $1.06, a decrease from the earlier projection of $1.07 to $1.20 [22]